User Settings
Article

[Anti-TNF (infliximab) treatment in Crohn disease: safety profile].

Antonio Carroccio,Lidia Di Prima,Giuseppe Pirrone,Giuseppe Ambrosiano,Davide Noto,Angelo B. Cefalù-2006-02-01-PubMed
3

TL;DRAbstract

Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma.

Chat with Paper

AI Agents for this Paper

Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma.

Keywords

InfliximabMedicineCrohn's diseaseTumor necrosis factor alphaLymphomaTumor necrosis factor αDiseaseInternal medicine

Chat

Click to start Chat